Post Bariatric Hypoglycemia Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts

DelveInsight's "Post Bariatric Hypoglycemia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Post Bariatric Hypoglycemia, historical and forecasted epidemiology as well as the Post Bariatric Hypoglycemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Post Bariatric Hypoglycemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Post Bariatric Hypoglycemia Market Forecast
https://www.delveinsight.com/sample-request/post-bariatric-hypoglycemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Post Bariatric Hypoglycemia Market Report:
• The Post Bariatric Hypoglycemia market size was valued ~USD 200 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In January 2025, MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, announced positive Phase 1 results from its single and multiple ascending dose (SAD/MAD) trial of MBX 1416 in healthy adults. MBX 1416, an investigational long-acting GLP-1 receptor antagonist, is being developed as a potential treatment for Post-Bariatric Hypoglycemia (PBH).
• In November 2024, MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in innovative precision peptide therapies for endocrine and metabolic disorders, has announced the completion of the final subject's last visit in its Phase 1 trial. The study, which included single and multiple ascending doses, evaluated MBX 1416, the company's long-acting glucagon-like peptide 1 (GLP-1) receptor antagonist, being developed to treat post-bariatric hypoglycemia (PBH).
• Among the emerging treatments, Eiger BioPharmaceuticals' AVEXITIDE is projected to achieve the largest market size during the forecast period (2024-2034).
• In 2023, the total number of postbariatric hypoglycemia cases across the 7MM was estimated at around 110,000, and according to DelveInsight's projections, this number is expected to rise by 2034.
• In 2023, the US represented the largest share of postbariatric hypoglycemia cases, accounting for approximately 80% of the total cases.
• According to DelveInsight's analysis, in 2023, sleeve gastrectomy cases had the highest incidence of postbariatric hypoglycemia in the US, followed by Roux-en-Y gastric bypass cases, with other surgical approaches showing fewer cases.
• In 2023, over 90% of postbariatric hypoglycemia cases in the United States were classified as mild to moderate in severity.
• In 2023, approximately 50,000 cases of postbariatric hypoglycemia were treated in the United States.
• Key Post Bariatric Hypoglycemia Companies: RECORDATI GROUP, Xeris Pharmaceuticals, Eiger BioPharmaceuticals, Zealand Pharma, Vogenx, Inc., and others
• Key Post Bariatric Hypoglycemia Therapies: Pasireotide Diaspartate, glucagon, Lyo avexitide, Dasiglucagon, Mizagliflozin, G-PumpTM (glucagon infusion), Avexitide, and others
• The Post Bariatric Hypoglycemia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Post Bariatric Hypoglycemia pipeline products will significantly revolutionize the Post Bariatric Hypoglycemia market dynamics.

Post Bariatric Hypoglycemia Overview
Post-bariatric hypoglycemia (PBH) is a condition that can occur after weight loss surgery, also known as bariatric surgery. This condition involves episodes of low blood sugar (hypoglycemia) that typically happen one to three hours after eating. Post-bariatric hypoglycemia is more commonly associated with certain types of weight loss procedures, such as gastric bypass surgery.

Get a Free sample for the Post Bariatric Hypoglycemia Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/post-bariatric-hypoglycemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Post Bariatric Hypoglycemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Post Bariatric Hypoglycemia Epidemiology Segmentation:
The Post Bariatric Hypoglycemia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Post Bariatric Hypoglycemia
• Prevalent Cases of Post Bariatric Hypoglycemia by severity
• Gender-specific Prevalence of Post Bariatric Hypoglycemia
• Diagnosed Cases of Episodic and Chronic Post Bariatric Hypoglycemia

Download the report to understand which factors are driving Post Bariatric Hypoglycemia epidemiology trends @ Post Bariatric Hypoglycemia Epidemiology Forecast
https://www.delveinsight.com/sample-request/post-bariatric-hypoglycemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Post Bariatric Hypoglycemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Post Bariatric Hypoglycemia market or expected to get launched during the study period. The analysis covers Post Bariatric Hypoglycemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Post Bariatric Hypoglycemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Post Bariatric Hypoglycemia Therapies and Key Companies
• Pasireotide Diaspartate: RECORDATI GROUP
• glucagon: Xeris Pharmaceuticals
• Lyo avexitide: Eiger BioPharmaceuticals
• Dasiglucagon: Zealand Pharma
• Mizagliflozin: Vogenx, Inc.
• G-PumpTM (glucagon infusion): Xeris Pharmaceuticals
• Avexitide: Eiger BioPharmaceuticals

Discover more about therapies set to grab major Post Bariatric Hypoglycemia market share @ Post Bariatric Hypoglycemia Treatment Landscape
https://www.delveinsight.com/sample-request/post-bariatric-hypoglycemia-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the Post Bariatric Hypoglycemia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Post Bariatric Hypoglycemia Companies: RECORDATI GROUP, Xeris Pharmaceuticals, Eiger BioPharmaceuticals, Zealand Pharma, Vogenx, Inc., and others
• Key Post Bariatric Hypoglycemia Therapies: Pasireotide Diaspartate, glucagon, Lyo avexitide, Dasiglucagon, Mizagliflozin, G-PumpTM (glucagon infusion), Avexitide, and others
• Post Bariatric Hypoglycemia Therapeutic Assessment: Post Bariatric Hypoglycemia current marketed and Post Bariatric Hypoglycemia emerging therapies
• Post Bariatric Hypoglycemia Market Dynamics: Post Bariatric Hypoglycemia market drivers and Post Bariatric Hypoglycemia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Post Bariatric Hypoglycemia Unmet Needs, KOL's views, Analyst's views, Post Bariatric Hypoglycemia Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.